We Do Not Currently List Keeps
We do not track current pricing for Keeps for hair loss treatment, so we cannot compare it here. Check pricing and availability with Keeps directly.
Browse Hair Loss Providers
Hair Loss Providers We Compare
Providers we currently list, with pricing we track
Regulatory noticeRegulatory note (verified October 31, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. The letter cites two lines of Hims marketing for compounded semaglutide: one presenting it as having the same active ingredient as Ozempic and Wegovy, and one making a clinical-evidence claim for its ingredients. Compounded drug products are not FDA-approved, and the agency’s position is that phrasing of this sort suggests otherwise, which in its view makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. When we checked FDA’s warning letter index on November 14, 2026 it showed no response letter and no close-out letter, so treat this as open. Read the FDA letter
Regulatory noticeRegulatory note (verified October 31, 2026): Hers is a brand of Hims & Hers Health, Inc., and the FDA wrote to that company twice on September 9, 2025, once for each brand. The Hers letter, MARCS-CMS 716825, went to chief executive Andrew Dudum after an August 2025 review of forhers.com. It cites two claims made for compounded semaglutide: one describing a weekly GLP-1 injection as having the same active ingredient as Ozempic and Wegovy, and one making a clinical-evidence claim for its ingredients. The agency’s position is that compounded products carry no FDA approval, so claims like these imply a sameness with approved medicines that has not been established, which in its view makes the products misbranded. When we checked FDA’s warning letter index on November 14, 2026 it listed neither a response nor a close-out letter, so the matter stands open. Read the FDA letter
We review the providers we list on a regular basis, and we may list Keeps again in the future.